Retrospective analysis of tigecycline shows that it may be an option for children with severe infections

Abstract

Our findings suggest that tigecycline may be an option for children with severe infections. However, more prospective, controlled trials are required to objectively evaluate the efficacy and safety of tigecycline in children.

Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study

“…In our series, TGC was used in combination with other antibacterial agents in all cases. This is in line with recent reports on TGC use in the treatment of critically ill children . In a cohort study on 661 adults with pneumonia caused by KPC‐producing K pneumoniae , the survival improved only when at least two in vitro active antimicrobial agents were included in the regimen .…”

“…This is in line with recent reports on TGC use in the treatment of critically ill children. 15,32 In a cohort study on 661 adults with pneumonia caused by KPC-producing K pneumoniae, the survival improved only when at least two in vitro active antimicrobial agents were included in the regimen. 33 We also found low mortality in children with BSI when treated with TGC.…”

Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

“…Almost all of the available data regarding the use of tigecycline in infants and children younger than 8 years derive from small case series collected retrospectively. [3][4][5][6][7]10 Although optimal dosage has not been defined, the usual dose reported in different case series ranged from 1 to 2 mg/kg every 12 hours. 1 In a case report of 12-month old liver transplant recipient with XDR Acinetobacter baumannii bacteremia, it was found that a dose of 1 mg/kg every 12 hours (without loading dose) provided similar drug exposure (area under the curve, AUC) with adult and children aged 8 to 11 years old.…”

“…In different case series, the loading dose has been administered in the most pediatric patients but in infant patients it was not generally given. [3][4][5][6][7]10 All patients in this case series were preterm infants, so the loading dose was not given due to the lack of pharmacokinetics and pharmacodynamics analysis in this population.…”

“…1,2 The off-label use of tigecycline to treat serious infections (blood stream infections, urinary tract infections, nosocomial pneumonia, or meningitis) has been reported in the pediatric age group. [3][4][5][6][7] The majority of patients in these clinical series were beyond infancy, and it was stated that tigecycline was generally well tolerated except for gastrointestinal adverse events (nausea, vomiting, diarrhea, acute pancreatitis), prolonged coagulation times, and mild increase of transaminases. [3][4][5][6]8 However, there is only scant information on tigecycline use in newborn infants.…”